Evaluating the cost and clinical outcomes of changing type 2 diabetes mellitus patients from current DPP-4 inhibitor treatment to alogliptin in a primary care setting

Study identification

• EU PAS number:
  EUPAS29153
• Study ID:
  36281
• Official title and acronym:
  Evaluating the cost and clinical outcomes of changing type 2 diabetes mellitus patients from current DPP-4 inhibitor treatment to alogliptin in a primary care setting
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This is an retrospective, observational study to evaluate the cost and clinical outcomes of changing type 2 diabetes mellitus patients from current DPP-4 inhibitor treatment to alogliptin in a primary care setting. The study population include all T2DM patients who have had therapy changed from another DPP-4 inhibitor to alogliptin, in combination with other hypoglycaemic agent(s) in primary care.
• Study status:
  Finalised

Research institutions and networks

Institutions

Dr David Strain

Networks

UK Clinical Research Network

Study timelines

Date when funding contract was signed

Planned:03/02/2018

Actual:03/02/2018

Study start date

Planned:09/03/2018

Actual:09/03/2018

Date of final study report

Planned:29/06/2018

Actual:29/06/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Takeda

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable